Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study-Reference-Cited by-同舟云学术

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Published:2024-03 Issue:3 Volume:25 Page:388-399
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Daver Naval G,Montesinos Pau,DeAngelo Daniel J,Wang Eunice S,Papadantonakis Nikolaos,Todisco Elisabetta,Sweet Kendra L,Pemmaraju Naveen,Lane Andrew A,Torres-Miñana Laura,Thompson James E,Konopleva Marina Y,Sloss Callum M,Watkins Krystal,Bedse Gaurav,Du Yining,Malcolm Kara E,Zweidler-McKay Patrick A,Kantarjian Hagop M

Funder

ImmunoGen

Publisher

Elsevier BV

Reference30 articles.

1. Treatment for relapsed/refractory acute myeloid leukemia;Thol;HemaSphere,2021

2. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia;Mushtaq;Leuk Lymphoma,2021

3. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia;Ravandi;Clin Lymphoma Myeloma Leuk,2020

4. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia;Roboz;J Clin Oncol,2014

5. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia;DeAngelo;Blood,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking Boundaries: Immunotherapy for Myeloid Malignancies;Cancers;2024-08-06

2. AML treatment: conventional chemotherapy and emerging novel agents;Trends in Pharmacological Sciences;2024-05

3. Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature;Cancer;2024-04-15

4. Antibody–drug conjugates in acute myeloid leukaemia: more research needed;The Lancet Oncology;2024-03